Hello Group Inc. Announces Unaudited Financial Results for the Second Quarter of 2026

BEIJING, Sept. 3, 2026 /PRNewswire/ -- Hello Group Inc. (NASDAQ: MOMO) ("Hello Group" or the "Company"), a leading player in Asia's online social networking space, today announced its unaudited financial results for the second quarter of 2026.

Second Quarter of 2026 Highlights

- Net revenues decreased by 5.1% year over year to RMB2,486.0 million (US$366.4 million*) in the second quarter of 2026.

- Net revenues from overseas increased by 52.0% year over year to RMB672.7 million (US$99.1 million) in the second quarter of 2026.

- Net income attributable to the shareholders of Hello Group Inc. was RMB237.4 million (US$35.0 million) in the second quarter of 2026, compared to a net loss of RMB140.2 million in the same period of 2025.

- Non-GAAP net income attributable to the shareholders of Hello Group Inc. (note 1) was RMB273.9 million (US$40.4 million) in the second quarter of 2026, compared to a net loss of RMB96.0 million in the same period of 2025. In the second quarter of 2025, the Company accrued an additional withholding tax of RMB547.9 million related to dividends paid or payable by its wholly foreign-owned enterprise ("WFOE") in Chinese mainland to its offshore parent company in Hong Kong, Momo Hong Kong.

- Diluted net income per American Depositary Share ("ADS") was RMB1.52 (US$0.22) in the second quarter of 2026, compared to a diluted net loss per ADS of RMB0.84 in the same period of 2025.

- Non-GAAP diluted net income per ADS (note 1) was RMB1.75 (US$0.26) in the second quarter of 2026, compared to a diluted net loss per ADS of RMB0.58 in the same period of 2025.

- For Momo app, total paying users were 3.9 million for the second quarter of 2026, compared to 3.5 million for the same period last year, and 3.7 million for the previous quarter. Tantan had 0.5 million paying users for the second quarter of 2026 compared to 0.7 million for the same period last year and 0.6 million for the previous quarter.

First Half of 2026 Highlights

- Net revenues decreased by 5.2% year over year to RMB4,872.0 million (US$718.0 million) for the first half of 2026.

- Net revenues from overseas increased by 48.2% year over year to RMB1,270.1 million (US$187.2 million) for the first half of 2026.

- Net income attributable to the shareholders of Hello Group Inc. was RMB528.5 million (US$77.9 million) for the first half of 2026, compared to RMB217.8 million during the same period of 2025.

- Non-GAAP net income attributable to the shareholders of Hello Group Inc. (note 1) was RMB602.7 million (US$88.8 million) for the first half of 2026, compared to RMB307.7 million during the same period of 2025.

- Diluted net income per ADS was RMB3.33 (US$0.49) for the first half of 2026, compared to RMB1.27 during the same period of 2025.

- Non-GAAP diluted net income per ADS (note 1) was RMB3.80 (US$0.56) for the first half of 2026, compared to RMB1.80 during the same period of 2025.

"The Group maintained steady business momentum in the second quarter of 2026," commented Yan Tang, Chairman and CEO of Hello Group. "On the domestic front, Momo navigated external headwinds to sustain the healthy performance of our cash-cow business, while Tantan continued to strengthen its AI capabilities to enhance user experience and monetization efficiency. Overseas, our product portfolio shifted from single-product reliance to more balanced and diversified growth, with growing synergies across the portfolio."

Second Quarter of 2026 Financial Results

Net revenues

Total net revenues were RMB2,486.0 million (US$366.4 million) in the second quarter of 2026, a decrease of 5.1% from RMB2,620.4 million in the second quarter of 2025.

Value-added service revenues mainly include virtual gift revenues from various audio, video and text-based scenarios, and membership subscription revenues. Total value-added service revenues were RMB2,439.6 million (US$359.6 million) in the second quarter of 2026, a decrease of 5.4% from RMB2,579.3 million during the same period of 2025. The decrease was primarily due to (a) external factors that influenced the operational focus of certain broadcasters and agencies on Momo app, which are still in recovery; (b) weak consumer sentiment due to macro headwinds; and (c) to a lesser extent, a decline in Tantan resulting from a decline in user base. The decrease was partially offset by the revenue growth from our overseas apps, driven by the rapid expansion from multiple social entertainment and dating brands across our rich portfolio.

Other services revenues were RMB46.4 million (US$6.8 million) in the second quarter of 2026, compared to RMB41.1 million during the same period of 2025.

Net revenues from Chinese mainland decreased from RMB2,177.9 million in the second quarter of 2025 to RMB1,813.3 million (US$267.2 million) in the second quarter of 2026, primarily due to the decrease in net revenues from Momo app and Tantan app. Net revenues from overseas increased from RMB442.4 million in the second quarter of 2025 to RMB672.7 million (US$99.1 million) in the second quarter of 2026, driven by the growth of new audio- and video-based products in the Middle East and North Africa ("MENA") region, along with incremental revenue from dating brands outside of MENA.

Cost and expenses

Cost and expenses were RMB2,260.3 million (US$333.1 million) in the second quarter of 2026, an increase of 1.5% from RMB2,227.7 million in the second quarter of 2025. The increase was primarily attributable to: (a) an increase of RMB56.8 million (US$8.4 million) in production costs in connection with films; (b) increased marketing investments in our new overseas apps, partially offset by continued reductions in marketing expenses for our China apps; and (c) increased payment channel costs due to the growth of overseas businesses, which incur higher payment channel costs as a percentage of revenue. The increase was further partially offset by lower revenue-sharing costs with broadcasters on Momo app, despite higher revenue-sharing costs with virtual gift recipients on our overseas apps.

Non-GAAP cost and expenses (note 1) were RMB2,222.3 million (US$327.5 million) in the second quarter of 2026, compared to RMB2,183.6 million during the same period of 2025.

Income from operations

Income from operations was RMB238.0 million (US$35.1 million) in the second quarter of 2026, compared to RMB403.5 million during the same period of 2025.

Non-GAAP income from operations (note 1) was RMB276.1 million (US$40.7 million) in the second quarter of 2026, compared to RMB447.7 million during the same period of 2025.

Interest income

Interest income was RMB53.6 million (US$7.9 million) in the second quarter of 2026, compared to RMB105.5 million during the same period of 2025. The decrease was primarily attributable to: (a) a reduction in the total volume of interest-bearing funds, as a result of bank loan repayments, the distribution of a special cash dividend, settlement of withholding tax accrued for prior periods, certain acquisitions and investments, and payment under the Company's Share Repurchase Program; (b) a lower proportion of high-yield US dollar funds in the total funds; and (c) a drop in the yield of both US dollar and RMB funds due to falling market interest rates.

Other gain or loss, net

Other gain or loss, net was a net loss of RMB25.1 million (US$3.7 million) in the second quarter of 2026, primarily consisting of losses from unrealized fair value changes in short-term investments, mainly including paper gold.

Income tax expenses

Income tax expenses were RMB69.6 million (US$10.3 million) in the second quarter of 2026, compared to RMB638.4 million in the second quarter of 2025. The decrease was primarily attributable to the Company's accrual of an additional withholding tax of RMB547.9 million related to dividends paid or payable by its wholly foreign-owned enterprise ("WFOE") in Chinese mainland to its offshore parent company, Momo Hong Kong, in the second quarter of 2025.

Share of income on equity method investments

Share of income on equity method investments was RMB41.5 million (US$6.1 million) in the second quarter of 2026, compared to RMB13.4 million during the same period of 2025. The increase was primarily attributable to a higher unrealized gain in fair value change of an investment fund.

Net income (loss)

Net income was RMB238.4 million (US$35.1 million) in the second quarter of 2026, compared to a net loss of RMB139.4 million during the same period of 2025.

Non-GAAP net income (note 1) was RMB274.8 million (US$40.5 million) in the second quarter of 2026, compared to a net loss of RMB95.2 million during the same period of 2025.

Net income (loss) attributable to the shareholders of Hello Group Inc.

Net income attributable to the shareholders of Hello Group Inc. was RMB237.4 million (US$35.0 million) in the second quarter of 2026, compared to a net loss of RMB140.2 million during the same period of 2025.

Non-GAAP net income (note 1) attributable to the shareholders of Hello Group Inc. was RMB273.9 million (US$40.4 million) in the second quarter of 2026, compared to a net loss of RMB96.0 million during the same period of 2025.

Net income (loss) per ADS

Diluted net income per ADS was RMB1.52 (US$0.22) in the second quarter of 2026, compared to a diluted net loss per ADS of RMB0.84 in the second quarter of 2025.

Non-GAAP diluted net income per ADS (note 1) was RMB1.75 (US$0.26) in the second quarter of 2026, compared to a diluted net loss per ADS of RMB0.58 in the second quarter of 2025.

Cash and cash flow

As of June 30, 2026, the Company's cash, cash equivalents, short-term deposits, short-term investments, short-term restricted cash and long-term deposits totaled RMB8,542.4 million (US$1,259.0 million), compared to RMB8,677.6 million as of December 31, 2025.

Net cash provided by operating activities in the second quarter of 2026 was RMB642.3 million (US$94.

Texas Cardiac Arrhythmia Institute przy St. David's Medical Center jako pierwszy ośrodek w USA uczestniczy w badaniu innowacyjnego systemu mapowania serca i ablacji polem pulsacyjnym

News provided by

Texas Cardiac Arrhythmia Institute at St. David's Medical Center

Sep 03, 2026, 03:37 ET

AUSTIN, Teksas, 3 września 2026 r. /PRNewswire/ -- Texas Cardiac Arrhythmia Institute (TCAI) przy St. David's Medical Center został niedawno pierwszym ośrodkiem w Stanach Zjednoczonych uczestniczącym w badaniu klinicznym oceniającym bezpieczeństwo i skuteczność systemu nowej generacji do mapowania serca i ablacji polem pulsacyjnym u pacjentów z napadowym i przetrwałym migotaniem przedsionków. Pierwszy zabieg przeprowadził dr Andrea Natale, F., członek Heart Rhythm Society, American College of Cardiology oraz European Society of Cardiology, pełniący funkcję dyrektora medycznego TCAI i głównego badacza koordynującego badanie na świecie.

Migotanie przedsionków, najczęstszy rodzaj arytmii, dotyka milionów osób na całym świecie. Dochodzi do niego w sytuacji, gdy przedsionki serca pracują zbyt szybko i niemiarowo. Napadowe migotanie przedsionków to arytmia, której objawy utrzymują się przez siedem dni lub krócej, natomiast przetrwałe migotanie przedsionków trwa dłużej niż tydzień. Wczesne leczenie napadowego i przetrwałego migotania przedsionków może zmniejszyć ryzyko powstawania zakrzepów, udaru mózgu i niewydolności serca, a także zapobiec przejściu choroby w postać utrwaloną.

„Ablacja polem pulsacyjnym należy do najważniejszych osiągnięć elektrofizjologii ostatnich dekad. Prowadzone badanie kliniczne pozwoli lepiej określić bezpieczeństwo i skuteczność tej technologii w praktyce - powiedział dr Natale. - Texas Cardiac Arrhythmia Institute należy do czołówki ośrodków leczenia arytmii, wspierając rozwój technologii, które będą kształtować przyszłość elektrofizjologii".

Nowy system cewnikowy wykorzystuje pola elektryczne do ablacji wybranych tkanek serca bez stosowania skrajnie wysokiej lub niskiej temperatury, na której opierano dotychczasowe metody, co pozwala ograniczyć ryzyko uszkodzenia sąsiednich struktur. System obejmuje zaawansowaną technologię trójwymiarowego mapowania serca, która zapewnia szczegółowy obraz aktywności elektrycznej serca i pozwala lekarzom ocenić położenie cewnika oraz kontakt z tkanką przed dostarczeniem energii i po nim. W klasycznej ablacji cewnik wprowadzany jest do wnętrza serca i za pomocą bardzo wysokiej albo bardzo niskiej temperatury niszczy tkankę odpowiedzialną za nieprawidłowy rytm serca, co zwiększa ryzyko uszkodzenia okolicznych struktur.

TCAI to nowoczesne centrum elektrofizjologii z sześcioma pracowniami wyposażonymi w zaawansowaną technologię. Zespół uznanych elektrofizjologów wykonuje tam dużą liczbę zabiegów elektrofizjologicznych o najwyższym poziomie skomplikowania.

Share this article

Das Texas Cardiac Arrhythmia Institute am St. David's Medical Center beteiligt sich als erste Einrichtung in den USA an einer Studie zu einem innovativen System zur Kartierung und Pulsfeldablation

News provided by

Texas Cardiac Arrhythmia Institute at St. David's Medical Center

Sep 03, 2026, 03:37 ET

AUSTIN, Texas, 3. September 2026 /PRNewswire/ -- Das Texas Cardiac Arrhythmia Institute (TCAI) am St. David's Medical Center hat sich kürzlich als erste Einrichtung des Landes an einer klinischen Studie beteiligt, in der die Sicherheit sowie Wirksamkeit eines Mapping- und Pulsfeld-Ablationssystems der nächsten Generation zur Behandlung von Patienten mit paroxysmalem sowie persistierendem Vorhofflimmern untersucht werden. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., geschäftsführender medizinischer Leiter des TCAI und globaler Studienleiter der Studie, führte den ersten Eingriff durch.

Vorhofflimmern, die häufigste Form von Herzrhythmusstörungen, betrifft weltweit Millionen von Menschen. Es tritt auf, wenn die beiden Vorhöfe des Herzens zu schnell und unregelmäßig schlagen. Paroxysmales Vorhofflimmern ist eine Herzrhythmusstörung, deren Symptome höchstens sieben Tage andauern, während persistierendes Vorhofflimmern eine anhaltende Herzrhythmusstörung ist, die länger als eine Woche andauert. Eine frühzeitige Behandlung von paroxysmalem und persistierendem Vorhofflimmern kann das Risiko für Blutgerinnsel, Schlaganfall und Herzinsuffizienz senken – und möglicherweise verhindern, dass die Erkrankung in eine permanente Form übergeht.

„Die Pulsfeldablation stellt einen der bedeutendsten Fortschritte in der Elektrophysiologie seit Jahrzehnten dar, und diese klinische Studie wird Ärzten weltweit helfen, die Sicherheit und Wirksamkeit dieser Technologie besser zu verstehen", sagte Dr. Natale. „Das Texas Cardiac Arrhythmia Institute ist weiterhin führend in der Behandlung von Herzrhythmusstörungen und trägt dazu bei, Technologien voranzutreiben, die die Zukunft der Elektrophysiologie prägen werden."

Das neuartige Kathetersystem nutzt elektrische Felder, um gezielt Herzgewebe zu veröden, ohne dabei die bei herkömmlichen Ablationsverfahren eingesetzte extreme Hitze oder Kälte zu verwenden, wodurch das Risiko einer Schädigung umliegender Strukturen verringert wird. Das System verfügt über eine fortschrittliche 3D-Herzkartierungstechnologie, die eine detaillierte Darstellung der elektrischen Aktivität des Herzens liefert und Ärzten ermöglicht, die Position des Katheters und den Kontakt zum Gewebe vor und nach der Energieabgabe zu visualisieren. Bei einem herkömmlichen Ablationsverfahren wird ein Katheter in das Innere des Herzens eingeführt, wo er mithilfe extremer Hitze oder Kälte Gewebe zerstört, das mit Herzrhythmusstörungen in Zusammenhang steht. Dabei besteht ein erhöhtes Risiko, dass umliegende Strukturen beschädigt werden.

Das TCAI ist ein hochmodernes elektrophysiologisches Zentrum, das sechs mit modernster Technologie ausgestattete Labore umfasst, in denen eine Gruppe renommierter kardialer Elektrophysiologen eine große Anzahl der komplexesten elektrophysiologischen Verfahren durchführt.

Share this article

Texas Cardiac Arrhythmia Institute pri St. David's Medical Center sa zúčastňuje na skúšaní inovatívneho mapovacieho a pulzného ablačného systému ako prvý v USA

News provided by

Texas Cardiac Arrhythmia Institute at St. David's Medical Center

Sep 03, 2026, 03:37 ET

AUSTIN, Texas , 3. september 2026 /PRNewswire/ – Texas Cardiac Arrhythmia Institute (TCAI) pri St. David's Medical Center sa nedávno stal prvým zariadením v krajine, ktoré sa zúčastnilo klinického skúšania na vyhodnotenie bezpečnosti a účinnosti mapovacieho a pulzného ablačného systému novej generácie na liečbu pacientov s paroxyzmálnou a perzistujúcou fibriláciou predsiení. Prvý zákrok vykonal doktor Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., výkonný lekársky riaditeľ TCAI a globálny hlavný skúšajúci v štúdii.

Fibrilácia predsiení, najčastejší typ arytmie, postihuje milióny ľudí po celom svete. Nastáva vtedy, keď horné dve komory srdca bijú príliš rýchlo a s nepravidelným rytmom. Paroxyzmálna fibrilácia predsiení je arytmia s príznakmi, ktoré trvajú do sedem dní, zatiaľ čo perzistujúca fibrilácia predsiení je pretrvávajúca arytmia, ktorá trvá dlhšie ako týždeň. Včasná liečba paroxyzmálnej a perzistujúcej fibrilácie predsiení môže znížiť riziko vzniku krvných zrazenín, mozgovej príhody a srdcového zlyhania, pričom môže zabrániť tomu, aby sa ochorenie stalo trvalým.

„Ablácia pulzným poľom predstavuje jeden z najvýznamnejších pokrokov v elektrofyziológii za posledné desaťročia. Táto klinická štúdia pomôže lekárom na celom svete lepšie pochopiť bezpečnosť a účinnosť tejto technológie," povedal Dr. Natale. „Texaský inštitút pre srdcovú arytmiu je neustále v popredí starostlivosti o pacientov s arytmiami a pomáha rozvíjať technológie, ktoré budú formovať budúcnosť elektrofyziológie."

Nový katétrový systém využíva elektrické polia na abláciu cieleného srdcového tkaniva bez použitia nadmerného tepla či chladu používaného pri tradičnej ablácii, čo pomáha znižovať riziko poškodenia okolitých štruktúr. Systém zahŕňa pokročilú technológiu 3D mapovania srdca, ktorá poskytuje detailný pohľad na elektrickú aktivitu srdca a umožňuje lekárom vizualizovať polohu katétra aj kontakt s tkanivom pred dodaním energie aj po ňom. Počas tradičného ablačného zákroku sa do srdca zavádza katéter, ktorý pomocou extrémneho tepla alebo chladu ničí tkanivo spojené s abnormálnymi srdcovými rytmami, čím rastie riziko poškodenia okolitých štruktúr.

Inštitút TCAI je najmodernejšie elektrofyziologické centrum so šiestimi laboratóriami vybavenými pokročilou technológiou, kde skupina renomovaných srdcových elektrofyziológov vykonáva vysoký počet najzložitejších elektrofyziologických zákrokov.

Share this article

Texaský institut pro srdeční arytmie (TCAI) při St. David's Medical Center se jako první v USA zapojil do klinické studie zaměřené na inovativní systém mapování a ablace pomocí pulzního pole

News provided by

Texas Cardiac Arrhythmia Institute at St. David's Medical Center

Sep 03, 2026, 03:37 ET

AUSTIN, Texas, 3. září 2026 /PRNewswire/ -- Texaský institut pro srdeční arytmie (TCAI) při St. David's Medical Center se nedávno stal prvním zdravotnickým zařízením v zemi, které se zapojilo do klinické studie zaměřené na hodnocení bezpečnosti a účinnosti systému mapování a ablace pulzním polem nové generace určeného k léčbě pacientů s paroxysmální a perzistentní fibrilací síní. První zákrok provedl MUDr. Andrea Natale, F.H.R.S., F.A.C.C., F.E.S.C., výkonný lékařský ředitel TCAI a hlavní globální výzkumník této studie.

Fibrilace síní, nejčastější typ arytmie, postihuje miliony lidí na celém světě. Vzniká, když dvě horní srdeční komory bijí příliš rychle a v nepravidelném rytmu. Paroxysmální fibrilace síní je arytmie, jejíž příznaky trvají sedm dní nebo méně, zatímco perzistentní fibrilace síní je trvalá arytmie, která přetrvává déle než týden. Včasná léčba paroxysmální a perzistentní fibrilace síní může snížit riziko vzniku krevních sraženin, cévní mozkové příhody a srdečního selhání – a může zabránit tomu, aby se onemocnění stalo trvalým.

„Ablace pulzním polem představuje jeden z nejvýznamnějších pokroků v elektrofyziologii za dlouhá desetiletí a tato klinická studie pomůže lékařům na celém světě lépe porozumět bezpečnosti a účinnosti této technologie," uvedl dr. Natale. „Texaský institut pro srdeční arytmie zůstává v čele péče o pacienty s arytmiemi a přispívá k rozvoji technologií, které budou utvářet budoucnost elektrofyziologie."

Tento novátorský katétrový systém využívá elektrická pole k ablaci cílené srdeční tkáně bez použití nadměrného tepla či chladu, jaké se používají při tradiční ablaci, čímž pomáhá snížit riziko poškození okolních struktur. Systém zahrnuje pokročilou technologii 3D mapování srdce, která poskytuje detailní pohled na elektrickou aktivitu srdce a umožňuje lékařům vizualizovat polohu katétru a kontakt s tkání před dodáním energie i po něm. Během tradičního ablačního zákroku se katétr zavádí do vnitřku srdce a pomocí extrémního tepla nebo chladu ničí tkáň spojenou s abnormálními srdečními rytmy, což zvyšuje riziko poškození okolních struktur.

TCAI je špičkové elektrofyziologické centrum, které zahrnuje šest laboratoří vybavených nejmodernější technologií, kde tým renomovaných kardiologických elektrofyziologů provádí velké množství nejsložitějších elektrofyziologických zákroků.

Share this article

Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress

- Preclinical data provide mechanistic insight into bexicaserin's dual mode of action, increasing inhibitory while decreasing excitatory neuronal activity, suggesting a broader antiseizure activity in preclinical models of focal, generalized motor and absence seizures across different etiologies.¹

- Bexicaserin is currently being evaluated in the global Phase III DEEp Program for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs); Lundbeck will present clinical and preclinical research from the broader development program at the European Epilepsy Congress.²˒³

VALBY, Denmark, Sept. 3, 2026 /PRNewswire/ -- Lundbeck today announced that preclinical data on the dual mode of action of bexicaserin will be featured in an oral presentation at the European Epilepsy Congress in Athens, Greece, 5–9 September, alongside additional presentations of clinical and preclinical data from the bexicaserin development program. The oral presentation will highlight mechanistic data supporting the scientific rationale of bexicaserin's dual mode of action as an investigational, oral, highly-selective superagonist of the 5-HT2c receptor. Through this mechanism, bexicaserin has been shown in preclinical studies to increase inhibitory and decrease excitatory neuronal activity.¹

Developmental and epileptic encephalopathies, or DEEs, are a diverse group of rare and serious epilepsies characterized by treatment-resistant seizures, frequent epileptiform activity and developmental slowing or regression.³ People living with DEEs may experience multiple seizure types that evolve over time, while the conditions arise from a wide range of underlying etiologies.³ There are currently no antiseizure medications approved across all DEEs, underscoring the need for new treatment approaches.⁴

"The data being presented at the European Epilepsy Congress highlight the strong scientific rationale for bexicaserin and its dual mode of action," said Tarek Samad, Executive Vice President and Head of Research & Development at Lundbeck. "DEEs are rare, serious and highly heterogeneous epilepsies, with a substantial unmet need for new treatment approaches. These presentations reflect our continued commitment to advancing the global Phase III DEEp program for people living with DEEs, and to deepen our scientific and mechanistic understanding of bexicaserin's mode of action."

The preclinical data are relevant because many DEEs are associated with network hyperexcitability where an increase in excitation, decrease in inhibition, or both, can lead to seizures.5 In hippocampal brain tissue, bexicaserin increases inhibitory while decreasing excitatory neuronal activity, suggesting broad-spectrum antiseizure activity in preclinical models of different seizure types from various etiologies. The high affinity and selectivity of bexicaserin for 5-HT2C receptor supports the conclusion that these effects are mediated through this receptor.1

Bexicaserin is being evaluated in the global Phase III DEEp Program. The program includes DEEp OCEAN in children and adults living with DEEs, including Lennox–Gastaut syndrome, and DEEp SEA in children and adults living with Dravet syndrome.6˒7

Bexicaserin is an investigational compound that is not approved for marketing by any regulatory authority worldwide. The efficacy and safety of bexicaserin have not been established.

Lundbeck's scientific presentations at the European Epilepsy Congress

About DEEs

Developmental and Epileptic Encephalopathies (DEEs) are a group of rare neurodevelopmental disorders that typically manifest in early childhood.³ These heterogeneous and severe epilepsy syndromes are characterized by refractory seizures, frequent epileptiform activity on electroencephalogram (EEG), and developmental stagnation or regression.³ According to the International League Against Epilepsy (ILAE), DEEs currently encompass more than 10 syndromes, including Early Infantile DEE (EIDEE), Infantile Epileptic Spasms Syndrome (IESS), Dravet Syndrome, and Lennox-Gastaut Syndrome with various etiologies, among those mainly genetic (e.g., CDKL5, STXBP1, KCNT1, SCN2A).

About bexicaserin

Bexicaserin (LP352) is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist with no engagement of the 5-HT2B and 5-HT2A receptor subtypes, potentially minimizing the risk of cardiovascular toxicity.8 The most common TEAEs associated with bexicaserin in the PACIFIC trial were somnolence, decreased appetite, constipation, diarrhea, lethargy, tremor, urinary tract infection, fatigue, pyrexia, agitation, and hypertension.

Bexicaserin acts via a dual mode of action, both increasing inhibitory and decreasing excitatory neuronal function, consistent with the reduction in seizures associated with DEEs arising from various etiologies.¹ Bexicaserin is being evaluated in a global Phase III clinical program (the DEEp Program). The FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with DEEs for patients two years of age and older. Bexicaserin has also been granted Breakthrough Therapy Designation in China for the treatment of seizures associated with DEEs.²

About DEEp OCEAN trial

DEEp OCEAN (NCT:06719141) is a Phase III interventional, randomized, double-blind, parallel-group, placebo-controlled trial evaluating bexicaserin in children and adults with DEEs, including LGS.6

The trial comprises a screening period of up to 35 days, followed by a 15-week treatment period consisting of a 3-week titration phase and a 12-week maintenance phase. Participants are randomized to receive either bexicaserin or placebo three times daily, with weight-based dosing used for pediatric participants. Following treatment, participants complete a taper period and safety follow-up or may transition into the 52-week DEEp open-label extension study (OLE). The aim of the trial is to evaluate the efficacy, safety, and tolerability of bexicaserin in reducing countable motor seizure frequency in patients with DEEs, including LGS.

About the DEEp SEA trial

DEEp SEA (NCT:06660394) is a Phase III interventional, randomized, double-blind, parallel-group, placebo-controlled trial evaluating bexicaserin in children and adults with Dravet syndrome.7 The trial is currently enrolling participants globally.

The trial comprises a screening period of up to 35 days, followed by a 15-week treatment period consisting of a 3-week titration phase and a 12-week maintenance phase. Participants are randomized to receive either bexicaserin or placebo three times daily, with weight-based dosing used for pediatric participants. Following treatment, participants complete a taper period and safety follow-up or may transition into the 52-week DEEp OLE. The aim of the trial is to evaluate the efficacy, safety, and tolerability of bexicaserin in reducing countable motor seizure frequency in patients with Dravet syndrome.

Contacts

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site and connect with us via LinkedIn.

References

- Bastlund JF, et al. Presented at EEC 2026, Athens, Greece.

- Bialer M, et al. Epilepsia. 2026. doi:10.1002/epi.70346.

- Scheffer IE, et al. Epilepsia. 2025;66:1014–1023.

- Scheffer IE, et al. Nat Rev Dis Primers. 2024;10:61.

- Guerrini R, et al. Physiol Rev. 2023;103(1):433–513.

- ClinicalTrials.gov. NCT06719141.

- ClinicalTrials.gov. NCT06660394.

- Ren A, et al. J Med Chem. 2025;68(11):10599–10618.

- Vossler DG, et al. Presented at EEC 2026, Athens, Greece.

- Sylvia C, et al. Presented at EEC 2026, Athens, Greece.

- Vermudez SAD, et al. Presented at EEC 2026, Athens, Greece.

CONTACT: 

H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark

+45 3630 1311

info@lundbeck.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

Laifen Unveils Its Biggest Personal Care Portfolio Yet at IFA 2026

Global personal care technology brand Laifen brings innovation within reach with new intelligent beauty innovations as it continues its evolution beyond hair care

BERLIN, Sept. 3, 2026 /PRNewswire/ -- Laifen, recognised by Euromonitor International as the world's No.1 high-speed hair dryer brand, will enter a new chapter at IFA 2026 (Hall 9, Booth 125). Showcasing its biggest product portfolio to date - including the AutoCurl Curling Iron, Glowy Vanity Mirror and Wave Lite Electric Toothbrush - the company will unveil a new generation of beauty, grooming and oral care innovations as it accelerates its transformation into a global personal care technology brand.

Since redefining the high-speed hair dryer category and guided by its new brand philosophy, "Laifen, Innovation within Reach," the brand continues to apply its engineering expertise beyond hair care. Built around its proprietary motor technology, intelligent sensing capabilities and precision engineering, the brand is creating an interconnected ecosystem of beautifully designed personal care products that make everyday routines smarter, faster and more intuitive.

"IFA 2026 marks an exciting milestone as Laifen continues its evolution into a global personal care technology brand", said Romeo Luo, General Manager of International Business. "This year, we're proud to showcase our most comprehensive portfolio yet. We built our reputation by reimagining the everyday hair dryer, and today we're applying that same engineering expertise across every category we enter. 'Innovation Within Reach' reflects our belief that premium technology should be accessible to everyone. At IFA, visitors will experience firsthand how Laifen is shaping the future of intelligent personal care."

Visitors at IFA will experience Laifen's vision firsthand through an immersive booth showcasing its expanding ecosystem of beauty, oral care, grooming and hair care innovations. Alongside live demonstrations of its latest products, visitors can enjoy salon-style styling sessions with professional stylists, explore a Technology Showcase featuring Laifen's proprietary motor and servo technologies, and take part in the Interactive High-Speed Airflow Challenge for the chance to win exclusive prizes.

Powering the next generation of personal care

Among the highlights at this year's show is the AutoCurl Curling Iron, bringing intelligent automation to at-home hairstyling. Powered by a high-precision Direct Time-of-Flight (D-ToF) sensor and adaptive servo technology, it automatically detects, curls and releases hair, making salon-inspired styling faster, easier and more consistent for users of all skill levels.

Joining Laifen's beauty portfolio is the Glowy Vanity Mirror, designed to recreate studio-quality lighting at home. Featuring full-spectrum LED illumination with CRI Ra98 colour accuracy, intelligent 24GHz radar sensing and Smart Memory functionality, it provides precise lighting for makeup application, skincare routines and everyday grooming. Both the AutoCurl Curling Iron and Glowy Vanity Mirror are now available on Laifen's official website and Amazon.

Expanding the brand's oral care range, the Wave Lite Electric Toothbrush makes Laifen's WaveMotion brushing technology more accessible than ever. Combining wide-angle oscillation with high-frequency vibration, three brushing intensities and up to 50 days of battery life, Wave Lite delivers an effective yet intuitive brushing experience. The Wave Lite will debut at IFA and will be available at select retailers and on Amazon from September 24th, 2026.

These latest launches will be showcased alongside Laifen's award-winning hair care heritage, highlighting the brand's continued evolution from a high-performance hair care innovator into a global personal care technology leader.

- Neo and Neo Special: Laifen's premium flagship high-speed hair dryers that deliver strong airflow. Includes oil diffusion nourishing systems to keep hair healthy and streamline routine.

- Wave Pro: The world's first oscillation & vibration electric toothbrush.

- Air & Air Pro: Designed to deliver fast, intelligent drying through precision airflow and temperature control, all within a lightweight, compact design.

- P3, P3 Pro, T1 Pro Electric Shavers: Engineered for a close, comfortable shave with advanced precision technology and an ergonomic design

Europe continues to be one of Laifen's fastest-growing markets, with the brand strengthening retail and e-commerce partnerships with the likes of Boots, Costco and Media Markt while expanding product availability across the region. As demand grows for premium, technology-led personal care products, Laifen remains committed to delivering innovative solutions that seamlessly fit into consumers' daily lives.

Journalists, creators and industry partners are invited to visit Laifen at Hall 9, Booth 125 throughout IFA 2026 for hands-on demonstrations, guided booth tours and an exclusive first look at the brand's latest innovations. The brand will also be present at this year's Showstoppers. For more information, please visit Laifen's Website and follow @laifen_tech and on social media.

Share this article

- The operational partnership combines Lucid's direct market presence with Emil Frey France's proven automotive and importer expertise.

- Together, the two will deliver an exceptional customer experience in the French market.

- French customers will be able to experience the Lucid Air 1 and Lucid Gravity 2 for the first time at the Paris Motor Show in October.

AMSTERDAM, Sept. 3, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ: LCID), maker of the world's most advanced software-defined vehicles and technologies, today announced an operational partnership with Emil Frey, one of Europe's leading automotive groups, to support Lucid's market entry into France. The collaboration combines Lucid's import operations with Emil Frey France's extensive automotive expertise and operational capabilities, creating a model designed to deliver a seamless premium customer experience. This partnership marks the latest step in Lucid's European growth strategy and sets the stage for the brand's public debut at the Paris Motor Show (Mondial de l'Auto) next month.

For customers in France, the partnership means that Lucid will enter the market with a strong operational foundation. Through its own import organization, Lucid will retain full responsibility for its brand, commercial strategy, and customer experience, while Emil Frey France Import Division provides tailored operational services to support the customer experience across multiple functions. This partnership will support the introduction of Lucid's award-winning electric vehicle line-up in France, including the sedan, Lucid Air1 and the SUV, Lucid Gravity2, while enabling an efficient and scalable market launch.

"France is one of Europe's most important automotive markets and represents a key pillar of Lucid's expansion strategy," said Lawrence Hamilton, President of Europe at Lucid. "This partnership brings together our industry-leading vehicles and technology with Emil Frey's unparalleled operational expertise and customer support. Together, we are building the foundation to deliver exceptional customer experiences for years to come as we continue to grow our vehicle lineup."

"We are pleased to welcome Lucid as a partner," said Pierre Guignot, General Manager, Emil Frey France Import Division. "This collaboration reflects our commitment to supporting manufacturers that are redefining the automotive industry. Our role is one of a bespoke service partner, providing flexible operational services tailored to Lucid's specific requirements. Together, we are creating the conditions for a successful market launch in France."

French customers will be able to experience the Lucid brand for the first time at the Paris Motor Show, taking place October 12–18, 2026, at Porte de Versailles, where Lucid will present its vehicles as part of its official market introduction.

For more details about Lucid Motors and its products, visit the official Lucid international website: https://lucidmotors.com/fr-fr/subscribe

High-resolution images of the French market launch are available here: https://assets.lucidmotors.com/transfer/eb292e5d7f3d7a07240cd572e54c46cb454bab0f2124521ee090cb335dde963a

About Lucid Group

Lucid Group, Inc. (NASDAQ: LCID) is a technology company creating exceptional mobility experiences through innovation to drive the world forward. Built on Lucid's proprietary technology and software defined vehicle architectures, the company's lineup of award-winning vehicles brings Lucid's "Compromise Nothing™" approach to premium segments of the global automotive market. Lucid designs and engineers its products in-house and manufactures at its vertically integrated facilities in Arizona and Saudi Arabia, enabling continuous innovation across vehicles, software, and advanced driver assistance and autonomy-ready capabilities.

About Emil Frey France

Emil Frey France is one of the country's leading automotive distribution groups, operating across vehicle retail (Groupe Autosphere), industrial vehicles, agricultural machinery (Emil Frey Pro), spare parts distribution and manufacturing (MGA, Barrault, Green Valley), and used vehicle reconditioning (CRVO). It is the official importer of Mitsubishi Motors and Subaru in France. In 2025, the company sold more than 193,170 new and used vehicles, generated consolidated revenues of €4.7 billion (IFRS), and employs more than 10,000 people. Emil Frey France is the French subsidiary of the Emil Frey Group.

Trademarks 

This communication contains trademarks, service marks, trade names and copyrights of Lucid Group, Inc. and its subsidiaries and other companies, which are the property of their respective owners.

Media Contact

Sebastian Michel

PR & Communications Manager Europe at Lucid

preurope@lucidmotors.com

Camilla Jokisch

Lead PR & Communications Europe at Lucid

preurope@lucidmotors.com

Forward-Looking Statements

This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "shall," "expect," "anticipate," "believe," "seek," "target," "continue," "could," "may," "might," "possible," "potential," "predict" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Lucid's expansion in France and Europe, the expected benefits of Lucid's partnership with Emil Frey France, and the anticipated introduction and commercialization of Lucid vehicles in the French market. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Lucid's management. These forward-looking statements are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from these forward-looking statements. Many actual events and circumstances are beyond the control of Lucid. These forward-looking statements are subject to a number of risks and uncertainties, including those factors discussed under the cautionary language and the Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Qs, Current Reports on Form 8-K, and other documents Lucid has filed or will file with the Securities and Exchange Commission. If any of these risks materialize or Lucid's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Lucid currently does not know or that Lucid currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Lucid's expectations, plans or forecasts of future events and views as of the date of this communication. Lucid anticipates that subsequent events and developments will cause Lucid's assessments to change. However, while Lucid may elect to update these forward-looking statements at some point in the future, Lucid specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Lucid's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.

1) Lucid Air 325 - 920 kW (442 - 1.251 ch), autonomie combinée de 694 à 960 km (WLTP), 0 g CO₂/km, 11,8 à 19,1 kWh/100 km.

La consommation de carburant et les émissions de CO, d'un véhicule sont fonction non seulement de son rendement énergétique, mais également du comportement au volant et d'autres facteurs non techniques.

Les informations sur les consommations de carburant et les émissions de CO, de tous les modèles de voitures particulières neuves, contenues dans le guide de l'ADEME, peuvent être obtenues gratuitement dans tous les points de vente, auprès de l'ADEME et consultées sur le site internet : www.ademe.fr

2) Lucid Gravity 418 - 617 kW (568 - 839 ch), autonomie combinée de 536 à 739 km (WLTP), 0 g CO₂/km, 18,2 à 19,1 kWh/100 km.

La consommation de carburant et les émissions de CO, d'un véhicule sont fonction non seulement de son rendement énergétique, mais également du comportement au volant et d'autres facteurs non techniques.

Les informations sur les consommations de carburant et les émissions de CO, de tous les modèles de voitures particulières neuves, contenues dans le guide de l'ADEME, peuvent être obtenues gratuitement dans tous les points de vente, auprès de l'ADEME et consultées sur le site internet : www.ademe.fr 

Share this article

VICENZA, Italy, Sept. 3, 2026 /PRNewswire/ -- Vicenzaoro opens tomorrow, September 4, for a milestone edition for Italian Exhibition Group (IEG) and the global jewellery industry. Running until September 8, the trade show brings together around 1,300 exhibitors from 38 countries representing the entire supply chain, and buyers from more than 130 countries, while unveiling exhibition infrastructure and a deeper integration of technology within its distinctive Jewellery Boutique Show format.

At the centre of this transformation is the opening of the new Hall 2, a two-level, 23,000-square-metre building designed by GMP and part of a €60 million investment by IEG in the Vicenza exhibition centre. The infrastructure enhances the capacity and connectivity of the venue, supporting Vicenzaoro's evolution as a leading global trade platform.

Another development is the integration of T.Gold, which showcases jewellery manufacturing technologies, into the Vicenzaoro exhibition district.

Starting with this edition, T.Gold will be held in Hall 4 twice a year, in January and September. Reflecting the importance of technology as a driver of innovation and competitiveness, it will bring technologies and innovation such as additive manufacturing, automation, sustainability solutions and precious-material recovery, closer to the brands and manufacturers they serve.

"This edition marks an important milestone in the evolution of Vicenzaoro, but its significance extends well beyond the exhibition itself. By bringing technology to the show twice a year and connecting the entire jewellery value chain, we are strengthening Vicenzaoro's position as a global trade and knowledge platform where innovation, manufacturing, products and international markets converge. The industry is moving in this direction, and we want Vicenzaoro to be a strategic catalyst for that evolution," said Matteo Farsura, Global Exhibition Manager Jewellery & Fashion at Italian Exhibition Group.

The integration of T.Gold further reinforces the Jewellery Boutique Show format that distinguishes Vicenzaoro. The model brings specialised communities across the jewellery supply chain together within one exhibition ecosystem, from technology and manufacturing to finished jewellery, gemstones, components, watches and packaging.

In addition, Vicenzaoro September will host the CIBJO Centenary Congress. The World Jewellery Confederation's gathering, bringing together 400 key leaders from around the world in Vicenza, further highlights the city's role in the international gold community. With its new infrastructure, twice-yearly technology showcase and integrated value-chain approach, Vicenzaoro September 2026 marks a new phase for IEG and the global jewellery industry.

Share this article

VICENZA, Italien, 3. September 2026 /PRNewswire/ -- Die Vicenzaoro öffnet morgen, am 4. September, ihre Pforten für eine Jubiläumsausgabe, die für die Italian Exhibition Group (IEG) und die weltweite Schmuckbranche von besonderer Bedeutung ist. Die Messe, die bis zum 8. September dauert, bringt rund 1.300 Aussteller aus 38 Ländern zusammen, die die gesamte Lieferkette abdecken, sowie Einkäufer aus mehr als 130 Ländern. Dabei präsentiert sie im Rahmen ihres einzigartigen „Jewellery Boutique Show"-Formats neue Ausstellungsinfrastrukturen und eine noch stärkere Integration von Technologie.

Im Mittelpunkt dieser Umgestaltung steht die Eröffnung der neuen Halle 2, eines zweistöckigen, 23.000 Quadratmeter großen Gebäudes , das von GMP entworfen wurde und Teil einer 60-Millionen-Euro-Investition der IEG in das Messegelände von Vicenza ist. Die Infrastruktur verbessert die Kapazität und Anbindung des Veranstaltungsortes und unterstützt damit die Entwicklung der Vicenzaoro zu einer weltweit führenden Handelsplattform.

Eine weitere Neuerung ist die Integration der T.Gold, auf der Technologien zur Schmuckherstellung präsentiert werden, in das Messegelände der Vicenzaoro.

Ab dieser Ausgabe findet die T.Gold zweimal jährlich, im Januar und im September, in Halle 4 statt. Angesichts der Bedeutung der Technologie als Motor für Innovation und Wettbewerbsfähigkeit wird das Unternehmen Technologien und Innovationen wie additive Fertigung, Automatisierung, Nachhaltigkeitslösungen und die Rückgewinnung wertvoller Materialien näher an die Marken und Hersteller heranbringen, für die es tätig ist.

„Diese Ausgabe markiert einen wichtigen Meilenstein in der Entwicklung der Vicenzaoro, doch ihre Bedeutung reicht weit über die Messe selbst hinaus. Indem wir zweimal jährlich Technologie auf die Messe bringen und die gesamte Wertschöpfungskette der Schmuckbranche miteinander vernetzen, stärken wir die Position der Vicenzaoro als globale Handels- und Wissensplattform, auf der Innovation, Fertigung, Produkte und internationale Märkte zusammenlaufen. Die Branche bewegt sich in diese Richtung, und wir möchten, dass Vicenzaoro als strategischer Impulsgeber für diese Entwicklung fungiert ", sagte Matteo Farsura, Global Exhibition Manager Jewellery & Fashion bei der Italian Exhibition Group.

Die Einbindung von T.Gold stärkt das Format der „Jewellery Boutique Show" noch weiter, das Vicenzaoro auszeichnet. Das Modell vereint spezialisierte Fachkreise aus der gesamten Schmuck-Lieferkette in einem einzigen Messeökosystem – von Technologie und Fertigung bis hin zu fertigem Schmuck, Edelsteinen, Komponenten, Uhren und Verpackungen.

Darüber hinaus wird im Rahmen der Vicenzaoro im September der CIBJO-Kongress zum 100-jährigen Jubiläum stattfinden. Die Tagung der World Jewellery Confederation, zu der 400 führende Persönlichkeiten aus aller Welt in Vicenza zusammenkommen, unterstreicht einmal mehr die Rolle der Stadt in der internationalen Goldbranche. Mit ihrer neuen Infrastruktur, der zweimal jährlich stattfindenden Technologieausstellung und dem integrierten Wertschöpfungskettenansatz läutet die Vicenzaoro September 2026 eine neue Phase für die IEG und die globale Schmuckbranche ein.

Share this article